Fournier's gangrene: CT findings

Marco A. Amendola(Miami Transplant Institute), O. Galindez(University of Miami), Richard W. Joseph(Daiichi Sankyo (United States)), Rafael A. Antun(University of Miami), Javier Casillas(University of California, Los Angeles)

Abdominal Imaging

September 1, 1994

10.1007/bf00206944

Cited by 44

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

|The Lancet|2016|3.7k

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

|New England Journal of Medicine|2013|3.4k

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

|The Lancet|2016|2.2k

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

|The Lancet|2014|1.8k

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

|JAMA|2016|1.1k